[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355187-105":3,"doc-detail-355187-en":85,"detail-sidebar-cat-0-en-105":119},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","serum-long-noncoding-rna-fam83h-as1-serves-as-a-potential-noninvasive-diagnostic-biomarker-for-ovarian-cancer","Serum long noncoding RNA FAM83H-AS1 serves as a potential noninvasive diagnostic biomarker for ovarian cancer","","Serum long noncoding RNA FAM83H-AS1 is evaluated as a noninvasive biomarker for diagnosing and staging ovarian cancer, addressing uncertainty in its clinical diagnostic value. The study measured serum FAM83H-AS1 by RT-qPCR in 118 ovarian cancer patients, 73 individuals with benign ovarian disease, and 61 healthy controls, alongside CA125, HE4, and ROMA. Results show higher FAM83H-AS1 in cancer and advanced TNM/metastatic disease, strong ROC performance, and independent diagnostic association with worse progression-free survival.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/serum-long-noncoding-rna-fam83h-as1-serves-as-a-potential-noninvasive-diagnostic-biomarker-for-ovarian-cancer/355187/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/serum-long-noncoding-rna-fam83h-as1-serves-as-a-potential-noninvasive-diagnostic-biomarker-for-ovarian-cancer/355187.png","ImageObject",300,407,{"name":42,"@type":43},"Riley","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What role does FAM83H-AS1 play in the context of ovarian cancer diagnosis?","Question",{"text":63,"@type":64},"FAM83H-AS1 is assessed as a serum-based lncRNA biomarker that may help diagnose ovarian cancer and provide diagnostic value not previously clear.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was serum FAM83H-AS1 measured and compared among groups?",{"text":68,"@type":64},"Serum FAM83H-AS1 expression was quantified using RNA extraction followed by RT-qPCR, and results were compared across ovarian cancer patients, benign ovarian disease patients, and healthy controls.",{"name":70,"@type":61,"acceptedAnswer":71},"How does combining FAM83H-AS1 with ROMA affect diagnostic accuracy?",{"text":72,"@type":64},"The combined FAM83H-AS1 + ROMA panel achieved superior diagnostic performance (AUC 0.909) compared with FAM83H-AS1 alone (AUC 0.824).",{"name":74,"@type":61,"acceptedAnswer":75},"What prognostic relationship was found for serum FAM83H-AS1?",{"text":76,"@type":64},"Higher serum FAM83H-AS1 expression was an independent prognostic factor for decreased progression-free survival, while independent significance for overall survival was not supported after multivariate adjustment.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},355187,1790194123,{"code":4,"msg":86,"data":87},"success",{"doc_id":83,"user_id":88,"nickname":42,"user_avatar":89,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":90,"file_id":91,"file_url":92,"file_type":93,"file_size":94,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":95,"language":96,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":97,"faqs":98,"seo_title":99,"seo_description":12,"update_tm":100,"read_time":101,"preview_page_count":33,"preview_urls":102},1374391975076,"https://ap-avatar.wpscdn.com/avatar/14000253ca4ec9f6853?x-image-process=image/resize,m_fixed,w_180,h_180&k=1783305029341752051","Tian et al. Journal of Ovarian Research (2026) 19:83 Journal of Ovarian Research  \n[https://doi.org/10.1186/s13048-026-01995-1](https://doi.org/10.1186/s13048-026-01995-1)  \nRESEARCH Open Access  \nSerum long noncoding RNA FAM83H-AS1 serves as a potential noninvasive diagnostic biomarker for ovarian cancer  \nChunying Tian1, Hongshuai Sun1, Ruiyao Li1, Yuanyuan Chen1, Ting Li1, Xiaoming Su1 and Xiuyan Yu1*  \nAbstract  \nBackground The long noncoding RNA (lncRNA) FAM83H-AS1 plays a critical role in the development and progression of various cancers. This study evaluates the feasibility of serum FAM83H-AS1 as a diagnostic and staging marker for ovarian cancer (OC), addressing its previously unclear diagnostic value.  \nMethods Our study included 118 patients diagnosed with OC, 73 individuals with benign ovarian disease (BOD), and 61 healthy controls (HCs) . The expression of serum FAM83H-AS1 was quantified via RNA extraction followed by RT-qPCR. The levels of CA125 and HE4 were detected via a chemiluminescence microparticle immunoassay, and the risk of ovarian malignancy algorithm (ROMA) was calculated. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic effect of FAM83H-AS1 . Univariate and multivariate Cox regression analyses were employed to identify independent prognostic factors, while Kaplan–Meier analysis with the log-rank test was used to compare survival differences.  \nResults The levels of FAM83H-AS1 were significantly elevated in OC patients compared with those in individuals with BOD and HCs (P \u003C 0. 001) . Additionally, FAM83H-AS1 expression levels were markedly higher in advanced TNM stages and in cases of metastasis. ROC curve analysis demonstrated robust diagnostic performance for FAM83H-AS1 alone (AUC = 0 . 824), and the combined FAM83H-AS1 + ROMA panel achieved superior accuracy (AUC = 0 . 909) . Stepwise multivariate analysis identified FAM83H-AS1 as an independent diagnostic predictor for OC. A unit increase in this marker was associated with a 6 . 9% increase in the odds of OC (P = 0 . 030) . FAM83H-AS1 levels were positively correlated with TNM stage, lymphatic metastasis, distal metastasis, peritoneal metastasis, and established biomarkers (CA125, HE4, and ROMA; P \u003C 0. 05) . Notably, postoperative FAM83H-AS1 levels were significantly lower in 22 paired patients (P \u003C 0. 01), confirming its tumor-derived origin. Survival analysis indicated that elevated serum levels of FAM83H-AS1 expression serve as an independent prognostic factor associated with decreased progression-free survival (PFS) (HR = 8 . 251, P = 0 . 041) . However, it failed to exhibit independent prognostic significance for overall survival (OS), as the correlation with OS observed in the univariate analysis was rendered non-significant in the multivariate analysis after adjusting forTNM stage. Kaplan-Meier curves further validated significantly worse survival outcomes for patients categorized in the high-expression group (P \u003C 0. 05) .  \n*Correspondence:  \nXiuyan Yu[yuxiuyan1968@sohu.com](yuxiuyan1968@sohu.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creativ","cbCaicaMiZAhn6kp","https://ap.wps.com/l/cbCaicaMiZAhn6kp","pdf",2253327,14,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Keywords\n# Introduction","[{\"question\":\"What role does FAM83H-AS1 play in the context of ovarian cancer diagnosis?\",\"answer\":\"FAM83H-AS1 is assessed as a serum-based lncRNA biomarker that may help diagnose ovarian cancer and provide diagnostic value not previously clear.\"},{\"question\":\"How was serum FAM83H-AS1 measured and compared among groups?\",\"answer\":\"Serum FAM83H-AS1 expression was quantified using RNA extraction followed by RT-qPCR, and results were compared across ovarian cancer patients, benign ovarian disease patients, and healthy controls.\"},{\"question\":\"How does combining FAM83H-AS1 with ROMA affect diagnostic accuracy?\",\"answer\":\"The combined FAM83H-AS1 + ROMA panel achieved superior diagnostic performance (AUC 0.909) compared with FAM83H-AS1 alone (AUC 0.824).\"},{\"question\":\"What prognostic relationship was found for serum FAM83H-AS1?\",\"answer\":\"Higher serum FAM83H-AS1 expression was an independent prognostic factor for decreased progression-free survival, while independent significance for overall survival was not supported after multivariate adjustment.\"}]","Serum long noncoding RNA FAM83H-AS1 serves as a potential noninvasive diagnostic biomarker for ovarian cancer | PDF",1790116601,35,[103,107,111,115],{"page_no":22,"url":104,"width":105,"height":106},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/426de4699d4beae18d8ae2a0abdb8fb2.webp",983,1310,{"page_no":26,"url":108,"width":109,"height":110},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4cc228ede56ab179ffbf782bbaa7adb0.webp",982,1309,{"page_no":30,"url":112,"width":113,"height":114},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/249913a8f0152c54e498a12aa68025a1.webp",981,1308,{"page_no":33,"url":116,"width":117,"height":118},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1f929d15facc7aa2726f0d5d18a15ac2.webp",980,1306,{"code":4,"msg":86,"data":120},[121,125,129,133,138,143,148,151,156,159,163],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":122,"show_sort_weight":123,"slug":124},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":126,"show_sort_weight":127,"slug":128},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":130,"show_sort_weight":131,"slug":132},"Exam",70,"exam",{"id":134,"doc_module":4,"doc_module_name":25,"category_name":135,"show_sort_weight":136,"slug":137},5,"Comic",60,"comic",{"id":139,"doc_module":4,"doc_module_name":25,"category_name":140,"show_sort_weight":141,"slug":142},6,"Technology",50,"technology",{"id":144,"doc_module":4,"doc_module_name":25,"category_name":145,"show_sort_weight":146,"slug":147},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":149,"slug":150},30,"research-report",{"id":152,"doc_module":4,"doc_module_name":25,"category_name":153,"show_sort_weight":154,"slug":155},9,"Religion & Spirituality",20,"religion-spirituality",{"id":154,"doc_module":4,"doc_module_name":25,"category_name":157,"show_sort_weight":154,"slug":158},"World Cup","world-cup",{"id":160,"doc_module":4,"doc_module_name":25,"category_name":161,"show_sort_weight":160,"slug":162},10,"Lifestyle","lifestyle",{"id":164,"doc_module":4,"doc_module_name":25,"category_name":165,"show_sort_weight":134,"slug":166},19,"General","general"]